摘要
BackgroundCancer is currently the second leading cause of death globally. There is much uncertainty regarding the comparative risks of new-onset overall cancer and pre-specified cancer for Type 2 diabetes mellitus (T2DM) patients on sodium-glucose cotransporter 2 inhibitors (SGLT2I) versus DPP4I.Methods: This population-based cohort study patients included patients who were diagnosed with T2DM and administered either SGLT2 or DPP4 inhibitors between 1 January 2015 and 31 December 2020 in public hospitals of Hong Kong.Results: This study included 60,112 T2DM patients (mean baseline age: 62.1 +/- 12.4 years, male: 56.36%), of which 18,167 patients were SGLT2I users and 41,945 patients were dipeptidyl peptidase 4 inhibitor (DPP4I) users. Multivariable Cox regression found that SGLT2I use was associated with lower risks of all-cause mortality (HR: 0.92; 95% CI: 0.84-0.99; p= 0.04), cancer-related mortality (HR: 0.58; 95% CI: 0.42-0.80; p <= 0.001) and new diagnoses of any cancer (HR: 0.70; 95% CI: 0.59-0.84; p <= 0.001). SGLT2I use was associated with a lower risk of new-onset breast cancer (HR: 0.51; 95% CI: 0.32-0.80; p <= 0.001), but not of other malignancies. Subgroup analysis on the type of SGLT2I, dapagliflozin (HR: 0.78; 95% CI: 0.64-0.95; p = 0.01) and ertugliflozin (HR: 0.65; 95% CI: 0.43-0.98; p = 0.04) use was associated with lower risks of new cancer diagnosis. Dapagliflozin use was also linked to lower risks of breast cancer (HR: 0.48; 95% CI: 0.27-0.83; p = 0.001).Conclusion: Sodium-glucose cotransporter 2 inhibitor use was associated with lower risks of all-cause mortality, cancer-related mortality and new-onset overall cancer compared to DPP4I use after propensity score matching and multivariable adjustment.
学科与关键词
- Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetesZhou, Jiandong; Liu, Xuejin; Chou, Oscar Hou-In; Li, Lifang; Lee, Sharen; Wong, Wing Tak; Zhang, Qingpeng; Chang, Carlin; Liu, Tong; Tse, Gary; Jing, Fengshi*; Cheung, Bernard Man Yung*RHEUMATOLOGY, 2023, 62(4): 1501-1510.被引 12
- Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong KongLee, Sharen; Zhou, Jiandong; Leung, Keith Sai Kit; Wai, Abraham Ka Chung; Jeevaratnam, Kamalan; King, Emma; Liu, Tong; Wong, Wing Tak; Chang, Carlin; Wong, Ian Chi Kei; Cheung, Bernard Man Yung; Tse, Gary*; Zhang, Qingpeng*Cardiovascular Drugs and Therapy, 2023, 37(3): 561-569.被引 18
- Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor usersZhou, Jiandong; Lee, Sharen; Leung, Keith Sai Kit; Wai, Abraham Ka Chung; Liu, Tong; Liu, Ying; Chang, Dong; Wong, Wing Tak; Wong, Ian Chi Kei; Cheung, Bernard Man Yung; Zhang, Qingpeng*; Tse, Gary*ESC Heart Failure, 2022, 9(2): 1388-1399.被引 13
